An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis

.

Source: Expert Opinion on Biological Therapy - December 15, 2023 Category: Drugs & Pharmacology Authors: Alexandria MaticNouf AlfaidiVera BrilThe Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada Source Type: research